Synthesis 2021; 53(07): 1292-1300
DOI: 10.1055/s-0040-1706556
paper

(E)-3-Arylidene-4-diazopyrrolidine-2,5-diones: Preparation and Use in RhII-Catalyzed X–H Insertion Reactions towards Novel, Medicinally Important Michael Acceptors

Autoren

  • Evgeny Chupakhin

    a   Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, 199034, Russian Federation   eMail: m.krasavin@spbu.ru   eMail: d.dariin@spbu.ru
  • Martha Gecht

    a   Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, 199034, Russian Federation   eMail: m.krasavin@spbu.ru   eMail: d.dariin@spbu.ru
  • Alexander Ivanov

    a   Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, 199034, Russian Federation   eMail: m.krasavin@spbu.ru   eMail: d.dariin@spbu.ru
  • Grigory Kantin

    a   Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, 199034, Russian Federation   eMail: m.krasavin@spbu.ru   eMail: d.dariin@spbu.ru
  • Dmitry Dar’in

    a   Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, 199034, Russian Federation   eMail: m.krasavin@spbu.ru   eMail: d.dariin@spbu.ru
  • Mikhail Krasavin

    a   Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, 199034, Russian Federation   eMail: m.krasavin@spbu.ru   eMail: d.dariin@spbu.ru
    b   Immanuel Kant Baltic Federal University, Kaliningrad, 236016, Russian Federation

This research was supported by the Russian Foundation for Basic Research (project grant 19-33-60010).


Graphical Abstract

Abstract

The use of readily available 1-aryl-3-arylidenepyrrolidine-2,5-diones in high yielding direct diazo-transfer reactions and subsequent involvement of the resulting diazo compounds in RhII-catalyzed O–H, S–H, and N–H insertion reactions delivered 4-substituted 1-aryl-3-arylidenepyrrolidine-2,5-diones of defined regiochemistry and geometrical configuration. These products are intended to be studied as Michael acceptors capable of inhibiting thioredoxin reductase, a promising cancer target.

Supporting Information



Publikationsverlauf

Eingereicht: 14. September 2020

Angenommen nach Revision: 07. Oktober 2020

Artikel online veröffentlicht:
05. November 2020

© 2020. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany